

Company Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

Cellecstar Reports Financial Results for Year Ended December 31, 2019 and Provides a Corporate Update

Mar 9 2020, 8:00 AM EDT

Cellecstar Biosciences Announces CLR 131 Achieves Primary Efficacy Endpoints from Its Phase 2 CLOVER-1 Study in Relapsed/Refractory B-cell Lymphomas and Completion of the Phase 1 Relapsed/Refractory Multiple Myeloma Dose Escalation Study

Feb 19 2020, 8:00 AM EST

Cellecstar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

Jan 9 2020, 8:00 AM EST

Stock Overview

Symbol	CLRB	LifeSci Advisors
Exchange	Nasdaq	Monique Kosse
Market Cap	12.97m	Managing Director
Last Price	\$1.38	T: 646-915-3820
52-Week	\$1.04 - \$3.33	monique@lifesciadvisors.com

04/08/2020 04:00 PM EDT

Investor Relations

Management Team

James Caruso

President, CEO and Director

Igor Grachev, M.D., Ph.D.

Chief Medical Officer

Jarrod Longcor

Chief Business Officer

Dov Elefant

Vice President and Chief Financial Officer

Cellecstar Biosciences, Inc.

100 Campus Drive, Suite 207
Florham Park, NJ 07932

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.